Autophagy: Emerging therapeutic target for diabetic nephropathy

Seminars in Nephrology

Volumn 34, Issue 1, 2014, Pages 9-16

  Kume, Shinji ^a   Yamahara, Kosuke ^a   Yasuda, Mako ^a   Maegawa, Hiroshi ^a   Koya, Daisuke ^b  

^a ShigaUniversityofMedicalScience ^*  (Japan)

^b Diabetes andEndocrinologyKanazawaMedicalUniversity   (Japan)

Author keywords

AMPK; Autophagy; Diabetic nephropathy; MTORC1; Proteinuria

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1;

AUTOPHAGOSOME; AUTOPHAGY; COMPLEX FORMATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETOGENESIS; DRUG TARGETING; HEMODYNAMICS; HUMAN; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; METABOLIC STRESS; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION;

AMPK; AUTOPHAGY; DIABETIC NEPHROPATHY; MTORC1; PROTEINURIA;

ANIMALS; AUTOPHAGY; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY TUBULES, PROXIMAL; MULTIPROTEIN COMPLEXES; PODOCYTES; TOR SERINE-THREONINE KINASES;

EID: 84893384754     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2013.11.003     Document Type: Review

References (80)

1. Abbate M., Zoja C., Remuzzi G. How does proteinuria cause progressive renal damage?. J Am Soc Nephrol 2006, 17:2974-2984.
2. Burton C., Harris K.P. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996, 27:765-775.
3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
4. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 2000, 77:S3-12.
5. Forbes J.M., Thallas V., Thomas M.C., Founds H.W., Burns W.C., Jerums G., et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003, 17:1762-1764.
6. Ha H., Hwang I.A., Park J.H., Lee H.B. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 2008, 82(Suppl 1):S42-S45.
7. Hwang I., Lee J., Huh J.Y., Park J., Lee H.B., Ho Y.S., et al. Catalase deficiency accelerates diabetic renal injury through peroxisomal dysfunction. Diabetes 2012, 61:728-738.
8. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47:859-866.
9. Mallamaci F., Ruggenenti P., Perna A., Leonardis D., Tripepi R., Tripepi G., et al. ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol 2011, 22:1122-1128.
10. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
13. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
14. Ron D., Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007, 8:519-529.
15. Kroemer G., Marino G., Levine B. Autophagy and the integrated stress response. Mol Cell 2010, 40:280-293.
16. Mizushima N., Komatsu M. Autophagy. Renovation of cells and tissues. Cell 2011, 147:728-741.
17. Singh R., Kaushik S., Wang Y., Xiang Y., Novak I., Komatsu M., et al. Autophagy regulates lipid metabolism. Nature 2009, 458:1131-1135.
18. Yoshizaki T., Kusunoki C., Kondo M., Yasuda M., Kume S., Morino K., et al. Autophagy regulates inflammation in adipocytes. Biochem Biophys Res Commun 2012, 417:352-357.
19. Huber T.B., Edelstein C.L., Hartleben B., Inoki K., Dong Z., Koya D., et al. Emerging role of autophagy in kidney function, diseases and aging. Autophagy 2012, 8:1009-1031.
20. Hartleben B., Godel M., Meyer-Schwesinger C., Liu S., Ulrich T., Kobler S., et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010, 120:1084-1096.
21. Jiang M., Liu K., Luo J., Dong Z. Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury. Am J Pathol 2010, 176:1181-1192.
22. Kume S., Uzu T., Horiike K., Chin-Kanasaki M., Isshiki K., Araki S., et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 2010, 120:1043-1055.
23. Liu S., Hartleben B., Kretz O., Wiech T., Igarashi P., Mizushima N., et al. Autophagy plays a critical role in kidney tubule maintenance, aging and ischemia-reperfusion injury. Autophagy 2012, 8:826-837.
24. Periyasamy-Thandavan S., Jiang M., Wei Q., Smith R., Yin X.M., Dong Z. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int 2008, 74:631-640.
25. Takahashi A., Kimura T., Takabatake Y., Namba T., Kaimori J., Kitamura H., et al. Autophagy guards against cisplatin-induced acute kidney injury. Am J Pathol 2012, 180:517-525.
26. Kume S., Thomas M.C., Koya D. Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes 2012, 61:23-29.
27. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
28. Komatsu M., Waguri S., Ueno T., Iwata J., Murata S., Tanida I., et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 2005, 169:425-434.
29. Kuma A., Hatano M., Matsui M., Yamamoto A., Nakaya H., Yoshimori T., et al. The role of autophagy during the early neonatal starvation period. Nature 2004, 432:1032-1036.
30. Liang X.H., Jackson S., Seaman M., Brown K., Kempkes B., Hibshoosh H., et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402:672-676.
31. Pattingre S., Espert L., Biard-Piechaczyk M., Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 2008, 90:313-323.
32. Mizushima N., Yamamoto A., Matsui M., Yoshimori T., Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004, 15:1101-1111.
33. Komatsu M., Waguri S., Koike M., Sou Y.S., Ueno T., Hara T., et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007, 131:1149-1163.
34. Kawachi H., Miyauchi N., Suzuki K., Han G.D., Orikasa M., Shimizu F. Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 2006, 11:274-281.
35. Pagtalunan M.E., Miller P.L., Jumping-Eagle S., Nelson R.G., Myers B.D., Rennke H.G., et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997, 99:342-348.
36. Chen J., Chen M.X., Fogo A.B., Harris R.C., Chen J.K. mVps34 deletion in podocytes causes glomerulosclerosis by disrupting intracellular vesicle trafficking. J Am Soc Nephrol 2013, 24:198-207.
37. Cina D.P., Onay T., Paltoo A., Li C., Maezawa Y., De Arteaga J., et al. Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 2012, 23:412-420.
38. Oshima Y., Kinouchi K., Ichihara A., Sakoda M., Kurauchi-Mito A., Bokuda K., et al. Prorenin receptor is essential for normal podocyte structure and function. J Am Soc Nephrol 2011, 22:2203-2212.
39. Fang L., Zhou Y., Cao H., Wen P., Jiang L., He W., et al. Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury. PLoS One 2013, 8:e60546.
40. Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6:1122-1128.
41. Inoki K., Corradetti M.N., Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005, 37:19-24.
42. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
43. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
44. Huber T.B., Walz G., Kuehn E.W. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011, 79:502-511.
45. Lieberthal W., Levine J.S. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009, 20:2493-2502.
46. Godel M., Hartleben B., Herbach N., Liu S., Zschiedrich S., Lu S., et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011, 121:2197-2209.
47. Inoki K., Mori H., Wang J., Suzuki T., Hong S., Yoshida S., et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011, 121:2181-2196.
48. Lloberas N., Cruzado J.M., Franquesa M., Herrero-Fresneda I., Torras J., Alperovich G., et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006, 17:1395-1404.
49. Mori H., Inoki K., Masutani K., Wakabayashi Y., Komai K., Nakagawa R., et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun 2009, 384:471-475.
50. Sakaguchi M., Isono M., Isshiki K., Sugimoto T., Koya D., Kashiwagi A. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 2006, 340:296-301.
51. Hosokawa N., Hara T., Kaizuka T., Kishi C., Takamura A., Miura Y., et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009, 20:1981-1991.
52. Moscat J., Diaz-Meco M.T. Feedback on fat: p62-mTORC1-autophagy connections. Cell 2011, 147:724-727.
53. Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011, 13:132-141.
54. Nath K.A. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992, 20:1-17.
55. Risdon R.A., Sloper J.C., De Wardener H.E. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968, 2:363-366.
56. Kimura T., Takabatake Y., Takahashi A., Kaimori J.Y., Matsui I., Namba T., et al. Autophagy protects the proximal tubule from degeneration and acute ischemic injury. J Am Soc Nephrol 2011, 22:902-913.
57. Yang C., Kaushal V., Shah S.V., Kaushal G.P. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am J Physiol Renal Physiol 2008, 294:F777-F787.
58. Yamahara K., Kume S., Koya D., Tanaka Y., Morita Y., Chin-Kanasaki M., et al. Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J Am Soc Nephrol 2013, 24:1769-1781.
59. Colman R.J., Anderson R.M., Johnson S.C., Kastman E.K., Kosmatka K.J., Beasley T.M., et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:201-204.
60. Fontana L., Partridge L., Longo V.D. Extending healthy life span--from yeast to humans. Science 2010, 328:321-326.
61. Cherry Engelman RW, Wang B.Y., Kinjoh K., El-Badri N.S., Good R.A. Calorie restriction delays the crescentic glomerulonephritis of SCG/Kj mice. Proc Soc Exp Biol Med 1998, 218:218-222.
62. Kitada M., Takeda A., Nagai T., Ito H., Kanasaki K., Koya D. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res 2011, 2011:908185.
63. Kume S., Uzu T., Araki S., Sugimoto T., Isshiki K., Chin-Kanasaki M., et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 2007, 18:2715-2723.
64. Steinberg G.R., Kemp B.E. AMPK in health and disease. Physiol Rev 2009, 89:1025-1078.
65. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009, 9:563-575.
66. Alers S., Loffler A.S., Wesselborg S., Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012, 32:2-11.
67. Lee J.W., Park S., Takahashi Y., Wang H.G. The association of AMPK with ULK1 regulates autophagy. PLoS One 2010, 5:e15394.
68. Chang C.C., Chang C.Y., Wu Y.T., Huang J.P., Yen T.H., Hung L.M. Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase. J Biomed Sci 2011, 18:47.
69. Takiyama Y., Harumi T., Watanabe J., Fujita Y., Honjo J., Shimizu N., et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1alpha expression and oxygen metabolism. Diabetes 2011, 60:981-992.
70. Ding D.F., You N., Wu X.M., Xu J.R., Hu A.P., Ye X.L., et al. Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK. Am J Nephrol 2010, 31:363-374.
71. Lee M.J., Feliers D., Mariappan M.M., Sataranatarajan K., Mahimainathan L., Musi N., et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2007, 292:F617-F627.
72. Sharma K., Ramachandrarao S., Qiu G., Usui H.K., Zhu Y., Dunn S.R., et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008, 118:1645-1656.
73. Nakai A., Yamaguchi O., Takeda T., Higuchi Y., Hikoso S., Taniike M., et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007, 13:619-624.
74. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104:787-794.
75. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest 2006, 116:1756-1760.
76. Ebato C., Uchida T., Arakawa M., Komatsu M., Ueno T., Komiya K., et al. Autophagy is important in islet homeostasis and compensatory increase of beta cell mass in response to high-fat diet. Cell Metab 2008, 8:325-332.
77. Jung H.S., Chung K.W., Won Kim J., Kim J., Komatsu M., Tanaka K., et al. Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell Metab 2008, 8:318-324.
78. Kim K.H., Jeong Y.T., Oh H., Kim S.H., Cho J.M., Kim Y.N., et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 2013, 19:83-92.
79. Singh R., Xiang Y., Wang Y., Baikati K., Cuervo A.M., Luu Y.K., et al. Autophagy regulates adipose mass and differentiation in mice. J Clin Invest 2009, 119:3329-3339.
80. Lapierre L.R., Silvestrini M.J., Nunez L., Ames K., Wong S., Le T.T., et al. Autophagy genes are required for normal lipid levels in C. elegans. Autophagy 2013, 9:278-286.